- Home
- CATX vs CDXS Comparison
CATX vs CDXS Comparison
Compare CATX & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CATX
- CDXS
- Stock Information
- Founded
- CATX 1983
- CDXS 2002
- Country
- CATX United States
- CDXS United States
- Employees
- CATX N/A
- CDXS N/A
- Industry
- CATX Medical/Dental Instruments
- CDXS Major Chemicals
- Sector
- CATX Health Care
- CDXS Industrials
- Exchange
- CATX Nasdaq
- CDXS Nasdaq
- Market Cap
- CATX 182.9M
- CDXS 176.4M
- IPO Year
- CATX N/A
- CDXS 2010
- Fundamental
- Price
- CATX $2.34
- CDXS $2.46
- Analyst Decision
- CATX Strong Buy
- CDXS Buy
- Analyst Count
- CATX 10
- CDXS 2
- Target Price
- CATX $13.89
- CDXS $11.00
- AVG Volume (30 Days)
- CATX 619.9K
- CDXS 500.7K
- Earning Date
- CATX 05-12-2025
- CDXS 05-14-2025
- Dividend Yield
- CATX N/A
- CDXS N/A
- EPS Growth
- CATX N/A
- CDXS N/A
- EPS
- CATX N/A
- CDXS N/A
- Revenue
- CATX $1,454,000.00
- CDXS $59,345,000.00
- Revenue This Year
- CATX N/A
- CDXS $12.62
- Revenue Next Year
- CATX N/A
- CDXS $22.11
- P/E Ratio
- CATX N/A
- CDXS N/A
- Revenue Growth
- CATX 1.40
- CDXS N/A
- 52 Week Low
- CATX $1.60
- CDXS $1.90
- 52 Week High
- CATX $19.10
- CDXS $6.08
- Technical
- Relative Strength Index (RSI)
- CATX 51.17
- CDXS 51.79
- Support Level
- CATX $2.18
- CDXS $2.23
- Resistance Level
- CATX $2.65
- CDXS $2.59
- Average True Range (ATR)
- CATX 0.16
- CDXS 0.14
- MACD
- CATX 0.02
- CDXS 0.05
- Stochastic Oscillator
- CATX 56.25
- CDXS 70.45
About CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
About CDXS Codexis Inc.
Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.